Alexion Pharmaceuticals, Inc. (ALXN) Social Stream

Featured Post From StockTwits About ALXN

$AZN $ALXN Shares of AstraZeneca have gained +14% in the past three months against the Zacks Large Cap Pharmaceuticals industry’s gain of +10%. The Zacks analyst believes that AstraZeneca’s newer drugs, mainly cancer medicines Lynparza, Tagrisso and Imfinzi should keep driving revenues.

It has a strong pipeline with a number of phase III data readouts lined up for this year. Numerous external acquisitions and strategic collaborations are likely to boost AstraZeneca’s pipeline. The company has a record of earnings surprises in the recent quarters.

What Else are ALXN Traders Talking About?

Other tickers frequently mentioned alongside ALXN is AZN.